# Celsius Holdings, Inc.: Form 10-Q for the period ended Mar 31, 2023

- Company: [Celsius Holdings, Inc.](/companies/celh.md) (CIK 1341766)
- Form: 10-Q
- Filed: 2023-05-09
- Accepted by EDGAR: May 9, 2023, 16:22 ET
- Period: 2023-03-31
- Accession: 0000950170-23-019722
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1341766/000095017023019722/celh-20230331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1341766/000095017023019722/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 3 months, 2023-01-01 to 2023-03-31 | $146.1m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2023-01-01 to 2023-03-31 | $113.8m | us-gaap:GrossProfit |
| Research and development | 3 months, 2023-01-01 to 2023-03-31 | $300.0k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2023-01-01 to 2023-03-31 | $44.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2023-01-01 to 2023-03-31 | $8.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-01-01 to 2023-03-31 | $41.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2023-01-01 to 2023-03-31 | $0.40 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-01-01 to 2023-03-31 | $0.41 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-01-01 to 2023-03-31 | 78,759,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2023-01-01 to 2023-03-31 | −$13.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2023-01-01 to 2023-03-31 | $2.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2023-03-31 | $595.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-03-31 | $993.1m | us-gaap:AssetsCurrent |
| Total assets | at 2023-03-31 | $1.29bn | us-gaap:Assets |
| Current liabilities | at 2023-03-31 | $191.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-03-31 | $386.7m | us-gaap:Liabilities |
| Shareholders' equity | at 2023-03-31 | $81.0m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 14,170 characters.

When used in this report, unless otherwise indicated, the terms “the Company,” “Celsius,” “we,” “us” and “our” refer to Celsius Holdings, Inc. and its subsidiaries.

### Note Regarding Forward Looking Statements

This report contains forward-looking statements that reflect our current views about future events. We use the words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

Our forward-looking statements may include, but are not limited to, statements about:

- our expectations relating to expansion into additional geographic markets and product lines;
- our expectations relating to revenue, operating costs and profitability;
- our expectations regarding our strategy and investments;
- our expectations regarding our business, including market opportunity, consumer demand and our competitive advantage;
- our expectations regarding supply chains and distribution networks;
- the impact of future and existing food and drug laws and regulations on our business;
- our expectations regarding cost and availability of materials and ingredients;
- our expectations regarding our future growth prospects and our ability manage our growth and hire capable personnel to support our growth;
- the potential ongoing impact of the continuing COVID-19 pandemic on us directly, or on our distributors or suppliers;
- expected competition from the functional energy drink and supplement industries and other sources;
- our expectations relating to marketing and advertising expense;
- the timing of our receipt and recognition of revenues and other payments;
- our expectations about our trademarks and trade secrets;
- our expectations relating to macroeconomic conditions;
- general economic and business conditions in particular industries, markets or geographic regions, as well the potential for a significant economic slowdown, stagflation or economic recession;
- political unrest and military actions in foreign countries, particularly the armed conflict in Ukraine, as well as the impact on world markets and energy supplies resulting therefrom;
- our critical accounting policies and related estimates or changes in accounting practices;
- our liquidity and capital needs;
- political, legislative, regulatory and legal challenges;
- the merits or potential impact of any lawsuits filed against us or disputes we may be party to; and
- other statements regarding our future operations, financial condition, prospects and business strategies.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including but not limited to: our ability to successfully make and integrate acquisitions; the impact on our operations from public health crises, including the COVID-19 pandemic; and the performance, reliability and availability of our ecommerce platform and underlying network infrastructure.

### Business Overview

Celsius is a fast-growing company in the functional energy drink and liquid supplement categories in the United States and internationally. We engage in the development, processing, marketing, sale, and distribution of functional drinks and liquid supplements to a broad range of consumers. We believe that we provide differentiated products that offer clinically proven and innovative formulas meant to change the lives of our consumers for the better. We also believe that our brand is attractive to a broad range of customers including fitness enthusiasts.

Our flagship asset, Celsius, is a fitness supplement drink which accelerates metabolism and burns calories and body fat while providing energy. This product line comes in two versions, a ready-to-drink supplement format and an on-the-go powder form. We also offer a Celsius Heat and a Branch

Chain Amino Acids line, catered to both pre- and post-workout consumer needs. Our products are currently offered in major retail channels in the US including conventional grocery, natural, convenience, fitness, mass market, vitamin specialty and e-commerce.

An integral part of our value proposition is our focus on the functional energy drink and liquid supplement category, ensuring our products have clear and proven benefits. This is why we invest in research and development from the start and utilize our proprietary MetaPlus formulation in our portfolio, a blend of ginger root, guarana seed extract, chromium, vitamins, and green tea extract.

### Results of Operations

### Three months ended March 31, 2023 compared to three months ended March 31, 2022

### Revenue

For the three months ended March 31, 2023, revenue was approximately $259.9 million, an increase of $126.6 million or 94.9% from $133.4 million for the three months ended March 31, 2022. The total increase in revenue was largely attributable to increases in sales volume, as opposed to increases in product pricing. This growth was as a result of increased revenues from North America, where first quarter 2023 revenues were $248.6 million, an increase of $125.1 million or 101.3% from the same period in 2022. North America was driven by increases in distribution points and SKUs per location as well as some benefit from increased days inventory outstanding at the mixing centers of its largest distributor.

European revenues for the three months ended March 31, 2023 were $8.7 million, which increased by $0.2 million from the same period in 2022 due to foreign exchange rates and timing of new product launches. Asia revenues (which primarily consist of royalty revenues from our China licensee) contributed an additional $1.3 million, an increase of $0.3 million for the same period in 2022. Other international markets generated approximately $1.5 million in revenues during the three months ended March 31, 2023, an increase from $0.5 million for the same period in 2022.

The following table sets forth the amount of revenues by category and changes therein for the three months ended March 31, 2023 and 2022:

| Revenue Source | For the Three Months Ended March 31, 2023 | 2022 |
| --- | ---: | ---: |
| Total revenue | $259,939 | $133,388 |
| North America revenue | 248,552 | 123,473 |
| Europe revenue | 8,652 | 8,495 |
| Asia revenue | 1,258 | 966 |
| Other revenue | 1,477 | 454 |

### Gross Profit

For the three months ended March 31, 2023, gross profit increased by approximately $59.9 million or 111% to $113.8 million, from approximately $53.9 million for the three months ended March 31, 2022. Gross profit margins reflected an increase to 43.8% for the three months ended March 31, 2023 from 40.4% for the same period in 2022. The increase in gross profit dollars is related to increases in sales volumes, while the increase in gross profit margins is mainly related to our ability to leverage the increased volumes associated with our significant growth as well as a reduced mix of higher cost international cans, offset in part by some additional inventory write-offs and freight expense as we continue to integrate our business into the Pepsi distribution system across the U.S.

### Selling, General and Administrative Expenses

Selling, general and administrative expenses for the three months ended March 31, 2023 were $68.9 million, compared to $43.8 million for the three months ended March 31, 2022, an increase of $25.1 million. Marketing investment activities were increased by $16.5 million for the three months ended March 31, 2023 in comparison to the same period in 2022. Employee costs increased by $3.6 million, as we continued to invest in this area to have the proper infrastructure to support our growth. Administrative expenses amounted to $10.0 million or an increase of $5.5 million, approximately 100%, when compared to the same period in the prior year. This variance is mainly related to an increase in audit costs, legal expenses, insurance costs and office rent. Stock option expense for the three months ended March 31, 2023, was $5.5 million, an increase of $1.2 million from the same period in 2022. The change in stock option expense was mainly attributable to new awards to a growing employee base. Management deems it very important to motivate employees by providing them with ownership in the business in order to promote overperformance which translates into the continued success of our business based on key performance attributes. The remaining increases totaling $1.4 million were related to research and development, depreciation and amortization, and use and excise taxes. Lastly, this was offset by decreased storage and distribution as well as broker costs which accounted for a decrease of $3.0 million when compared to the three months ended March 31, 2022.

### Other Income (Expense)

Total other income (expense) for the three months ended March 31, 2023 and 2022 is mainly related to interest income which is offset by foreign currency exchange.

### Net Income Attributable to Common Stockholders

Net income attributable to common stockholders for the three months ended March 31, 2023 was $34.4 million or $0.41 per share based on a weighted average of approximately 76.7 million shares outstanding. In comparison, for the three months ended March 31, 2022, the Company had a net income attributable to common stockholders of approximately $6.7 million or $0.09 per share, based on a weighted average of 75.2 million shares outstanding. Diluted earnings per share was $0.40 and $0.09 for the three months ended March 31, 2023 and 2022, respectively.

### Liquidity and Capital Resources

As of March 31, 2023 and December 31, 2022, we had cash of approximately $633.6 million (including restricted cash of $38.1 million) and $652.9 million (including restricted cash of $38.8 million), respectively, and working capital of approximately $801.4 million and $756.7 million, respectively.

We believe that cash available from operations, including our cash resources, will be sufficient for our working capital needs, including purchase commitments for raw materials and inventory, increases in accounts receivable and other assets, and purchases of capital assets and equipment for the next twelve (12) months with respect to our current operating plan. Please refer to "Risk Factors" in Part 1, Item 1A, in our 2022 Annual Report for these and other factors that may have a material impact on our operations. Our primary sources of cash included cash from operations and proceeds from the issuance of Series A convertible preferred shares. These sources of cash are available to fund cash outflows that have both a short and long-term component.

Purchases of inventories, increases in accounts receivable and other assets, equipment (including coolers), advances for our co-packers, payments of accounts payable, and income taxes payable are expected to remain our principal recurring uses of cash.

Our current operating plan for the next twelve (12) months reflects sufficient financial resources.

### Cash flows (used in) provided by operating activities

Cash flows used in operating activities totaled approximately $13.8 million for the three months ended March 31, 2023, which compares to $9.1 million net cash provided by operating activities for the three months ended March 31, 2022. The approximately $22.9 million decrease in cash generation was primarily driven by the timing of cash receipts.

### Cash flows provided by (used in) investing activities

Cash flows provided by investing activities totaled approximately $1.0 million for the three months ended March 31, 2023, which compares to cash used in investing activities of $0.7 million for the three months ended March 31, 2022. The increase in the cash provided by investing activities when compared to the 2022 period was primarily due to proceeds on our note receivable, as we received approximately $3.2 million in March 2023. This was offset by an outlay of cash for property and equipment.

### Cash flows (used in) provided by financing activities

Cash flows used in financing activities totaled approximately $6.3 million for the three months ended March 31, 2023, which compares to cash provided by financing activities of $0.8 million for the three months ended March 31, 2022. The increase in cash used in financing activities is mainly related to the quarterly Pepsi dividend payment of $6.8 million.

### Off Balance Sheet Arrangements

As of March 31, 2023 and December 31, 2022, we had no off-balance sheet arrangements.

### Critical Accounting Policies and Estimates

Our consolidated financial statements are prepared in accordance with US GAAP, which requires us to make estimates and assumptions that affect the reported amounts in our consolidated financial statements. Critical accounting estimates are those that management believes are the most important to the portrayal of our financial condition and results and require the most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and that have had, or are reasonably likely to have, a material impact on our financial condition or results of operations. Judgments and uncertainties may result in materially different amounts being reported under different conditions or using different assumptions. There have been no material changes to our critical accounting policies or estimates from the information provided in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Part II, Item 8, "Financial Statements and Supplementary Data" (Note 2), included in our 2022 Annual Report for the fiscal year ended December 31, 2022.

## Market risk

As filed, 1,062 characters.

In the normal course of business our financial position is routinely subject to a variety of risks. The principal market risks (i.e., the risk of loss arising from adverse changes in market rates and prices) to which we are exposed are fluctuations in commodity and other input prices affecting the costs of our raw materials (including, but not limited to, increases in the costs of the price of aluminum cans, sucralose and other sweeteners, as well as other raw materials contained within our products). We generally do not use hedging agreements or alternative instruments to manage the risks associated with securing sufficient ingredients or raw materials. We are also subject to market risks with respect to the cost of commodities and other inputs because our ability to recover increased costs through higher pricing is limited by the competitive environment in which we operate.

We do not use derivative financial instruments to protect ourselves from fluctuations in interest rates and generally do not hedge against fluctuations in commodity prices.

## Controls and procedures

As filed, 5,708 characters.

### Management’s Report on Disclosure Controls and Procedures

Our Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal financial and accounting officer), conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of March 31, 2023, to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms adopted by the SEC, including to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our Chief Executive Officer and our Chief Financial Officer do not expect that our disclosure controls or internal controls will prevent all error and all fraud. Although our disclosure controls and procedures were designed to provide reasonable assurance of achieving their objectives and our Chief Executive Officer and our Chief Financial Officer are evaluating whether our disclosure controls and procedures are effective at doing so, a control system, no matter how well conceived and operated, can provide only reasonable, not absolute assurance that the objectives of the system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented if there exists in an individual a desire to do so. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

We identified material weaknesses as of December 31, 2022 in our internal controls over financial reporting, which were not fully remedied as of March 31, 2023. A material weakness is a deficiency or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected and corrected on a timely basis. As a result of these material weaknesses, we concluded that internal controls over the following areas were not effective as of December 31, 2022 and were not fully remedied as of March 31, 2023.

a) Management did not design effective information technology general controls (ITGCs) relating to appropriate segregation of duties over program change management for certain applications impacting the Company’s business processes that are relevant to the Company’s internal control over financial reporting; and

b) Management did not design and implement components of the COSO Framework to address all relevant risks of material misstatement, including elements of the control environment, information and communication, control activities and monitoring activities components, relating to the identification, design, implementation, and monitoring of sufficient business process controls related to the Company’s financial statement accounts to ascertain whether the components of internal control are present and functioning effectively.

#### Remediation Plan

As of the date of this Quarterly Report on Form 10-Q, management is re-assessing the design of controls and modifying processes designed to improve our internal control over financial reporting and remediate the control deficiencies that led to the material weaknesses, including but not limited to (a) improving consistency in change management supported by standard operating procedures to govern the authorization, testing and approval of changes to information technology systems supporting all of the Company’s internal control processes, (b) enhancing design and implementation of our control environment, including the expansion of formal accounting and IT policies and procedures and financial reporting controls, (c) continuing to identify and design and implement effective review and approval controls, and (d) implementing appropriate timely review and oversight responsibilities within the accounting and financial reporting functions.

### Changes in Internal Controls Over Financial Reporting

During the three months ended March 31, 2023, we have been implementing and will aggressively continue to implement changes that are both organizational and process-focused to improve the control environment. We anticipate the actions to be taken, and resulting process improvements, to generally strengthen our internal controls over financial reporting and information technology general controls which will address the material weaknesses noted as of December 31, 2022. These remedial measures were considered changes to our internal control environment which had a material effect on internal control over financial reporting. We will not be able to conclude whether the material weaknesses have been remediated until the completion of the December 31, 2023 annual report on Form 10-K.

## Risk factors

As filed, 507 characters.

We face a variety of risks that are inherent in our business and our industry, including operational, legal, regulatory and product risks. Such risks could cause our actual results to differ materially from our forward-looking statements, expectations and historical trends. Information about our most recent risk factors is disclosed in Part I, Item 1A “Risk Factors” in our 2022 Annual Report for the year ended December 31, 2022. At March 31, 2023, there have been no material changes to the information.

Filed May 9, 2023.
Source: SEC EDGAR, the filing index for accession 0000950170-23-019722. Last ingested by Listed: Nov 10, 2026, 02:33 ET. No prices; not investment advice.
